{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:46:46Z","timestamp":1790970406941,"version":"4.1.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic inflammatory skin conditions such as hidradenitis suppurativa and psoriasis vulgaris exhibit a significantly elevated prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), with studies indicating rates as high as 57% among affected individuals. This narrative review explores the underlying immunological mechanisms that connect HS and psoriasis with MASLD, emphasising the role of chronic systemic inflammation, immune dysregulation, and shared immunologic links between the diseases. This article also urges for enhanced awareness among dermatologists regarding the potential pharmacological interventions for patients with concurrent HS or psoriasis and MASLD, including glucagon-like peptide-1 receptor agonists and biologics, while acknowledging the need for further research to elucidate the efficacy and safety of these treatments.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1831174","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:53:58Z","timestamp":1781258038000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei Qiang","family":"Chng","sequence":"first","affiliation":[{"name":"Department of Dermatology, National Skin Centre","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake J.","family":"Liew","sequence":"additional","affiliation":[{"name":"Hwa Chong Institution","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon Fong","family":"Liew","sequence":"additional","affiliation":[{"name":"Specialist Care Group, Diabetes and Endocrinology Centre, Mount Elizabeth Medical Centre","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Muthiah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]},{"name":"National University Centre for Digestive Health, National University Hospital","place":["Singapore, Singapore"]},{"name":"National University Centre for Organ Transplantation, National University Hospital","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[{"name":"MAFLD Research Center. Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]},{"name":"Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, the First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel H.","family":"Oon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Skin Centre","place":["Singapore, Singapore"]},{"name":"National Skin Centre and Skin Research Institute of Singapore","place":["Singapore, Singapore"]},{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University","place":["Singapore, Singapore"]},{"name":"Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis suppurativa","volume":"405","author":"Sabat","year":"2025","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3597","article-title":"HS is associated with non-alcoholic fatty liver disease: a cross-sectional study","volume":"100","author":"Gonz\u00e1lez-Villanueva","year":"2020","journal-title":"Acta Dermato Venereol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15764","article-title":"High prevalence of non-alcoholic fatty liver disease among HS patients independent of classic metabolic risk factors","volume":"33","author":"Dur\u00e1n-Vian","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.11.008","article-title":"Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"65","author":"Brown","year":"2016","journal-title":"Metabolism"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.04.019","article-title":"Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis","volume":"47","author":"Rivera","year":"2007","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01169","article-title":"Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1159\/000131424","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.10.009","article-title":"The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease","volume":"35","author":"Sawada","year":"2023","journal-title":"Cell Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00193.2013","article-title":"IFN-gamma deficiency attenuates hepatic inflammation and fibrosis in a steatohepatitis model induced by a methionine- and choline-deficient high-fat diet","volume":"305","author":"Luo","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","article-title":"Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice","volume":"143","author":"Meng","year":"2012","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.11.004","article-title":"Emerging role of the IL-36\/IL-36R axis in multiple inflammatory skin diseases","volume":"144","author":"Ahmad","year":"2024","journal-title":"J Investig Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031120","article-title":"Psoriasis pathophysiology: current concepts of pathogenesis","volume":"64","author":"Krueger","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i41.9096","article-title":"Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis","volume":"22","author":"Chackelevicius","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12865-017-0215-y","article-title":"The imbalance of Th17\/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice","volume":"18","author":"He","year":"2017","journal-title":"BMC Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.05.020","article-title":"Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma","volume":"30","author":"Gomes","year":"2016","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1042\/cs20150405","article-title":"The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice","volume":"130","author":"Rolla","year":"2016","journal-title":"Clin Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4049\/jimmunol.1501175","article-title":"Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of th17 cells in the liver and an increased th17\/resting regulatory T cell ratio in peripheral blood and in the liver","volume":"196","author":"Rau","year":"2016","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973075","article-title":"TNF-alpha alters visfatin and adiponectin levels in human fat","volume":"39","author":"Hector","year":"2007","journal-title":"Horm Metab Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0305217","article-title":"Exploring the pathogenesis and immunological profiles of psoriasis complicated with MASLD","volume":"19","author":"Tan","year":"2024","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1593253","article-title":"The impact of innate immunity and epigenetics in the pathogenesis of HS","volume":"16","author":"Burke","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-016-0492-2","article-title":"Expression of MiRNA-155, MiRNA-223, MiRNA-31, MiRNA-21, MiRNA-125b, and MiRNA-146a in the inflammatory pathway of HS","volume":"40","author":"Hessam","year":"2017","journal-title":"Inflammation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18473","article-title":"Methylated MiRNAs may serve as potential biomarkers and therapeutic targets for HS","volume":"36","author":"Radhakrishna","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312869","article-title":"miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression","volume":"67","author":"Hanin","year":"2018","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202501627r","article-title":"Downregulation of HDAC9 alleviates autophagy dysfunction by inducing acetylation of ATG4B in metabolic dysfunction-associated steatotic liver disease","volume":"39","author":"Ma","year":"2025","journal-title":"FASEB J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15904","article-title":"Adipokines are dysregulated in patients with HS","volume":"178","author":"Malara","year":"2018","journal-title":"Br J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/mcg.0b013e3181ec5c66","article-title":"The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on review of the literature","volume":"45","author":"Polyzos","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2017.09.007","article-title":"HS and the metabolic syndrome","volume":"36","author":"Ergun","year":"2018","journal-title":"Clin Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00403-019-02018-4","article-title":"Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa","volume":"312","author":"Gonz\u00e1lez-L\u00f3pez","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/jcm12020663","article-title":"Adiponectin, leptin and resistin in patients with psoriasis","volume":"12","author":"S\u0142uczanowska-G\u0142abowska","year":"2023","journal-title":"J Clin Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/hc9.0000000000000639","article-title":"Adipokines regulate the development and progression of MASLD through organellar oxidative stress","volume":"9","author":"Zhao","year":"2025","journal-title":"Hepatol Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1800","article-title":"The influence of body weight on the prevalence and severity of HS","volume":"94","author":"Kromann","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i41.7113","article-title":"Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: inflammatory crosstalk that needs a multidisciplinary approach","volume":"27","author":"Perez-Carreras","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2026.1753","article-title":"Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial","volume":"15","author":"Lebwohl","year":"2026","journal-title":"JAMA Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216292","article-title":"The therapeutic potential of GLP-1 receptor agonists in the management of HS: a systematic review of anti-inflammatory and metabolic effects","volume":"13","author":"Krajewski","year":"2024","journal-title":"J Clin Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon\u2010like peptide\u20101 receptor agonist liraglutide on psoriasis in glucose\u2010tolerant patients \u2013 a randomized placebo\u2010controlled trial","volume":"29","author":"Faurschou","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.01.016","article-title":"Tolerability and safety of concomitant GLP-1 receptor agonist and biologic therapy: a retrospective chart review","volume":"94","author":"Khang","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-337431","article-title":"Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities","volume":"75","author":"Zhou","year":"2025","journal-title":"Gut"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051934","article-title":"Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis","volume":"12","author":"Hagino","year":"2023","journal-title":"J Clin Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16835","article-title":"Real-world safety and effectiveness of adalimumab in patients with HS: a 52-week analysis of a postmarketing surveillance study in Japan","volume":"50","author":"Hayashi","year":"2023","journal-title":"J Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"17562848251335824","DOI":"10.1177\/17562848251335824","article-title":"MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review","volume":"18","author":"Gonz\u00e1lez Fern\u00e1ndez","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.033","article-title":"Long-term safety of nine systemic medications for psoriasis: a cohort study using the Spanish Registry of adverse events for biological therapy in dermatological diseases (BIOBADADERM) registry","volume":"83","author":"Daud\u00e9n","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0040","article-title":"Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: directed acyclic graphs","volume":"28","author":"Takamura","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"B47","unstructured":""},{"key":"B48","unstructured":""},{"key":"B49","unstructured":""}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831174\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:54:03Z","timestamp":1781258043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831174\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2026.1831174"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1831174","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1831174"}}